medigraphic.com

2002, Número S1

<< Anterior Siguiente >>

Arch Cardiol Mex 2002; 72 (S1)


Tratamiento del paciente asintomático sobreviviente de un infarto del miocardio extenso

Lacy NMC

Idioma: Español
Referencias bibliográficas: 22
Paginas: 100-105
Archivo PDF: 65.86 Kb.


RESUMEN

Los pacientes que sobreviven a un infarto agudo del miocardio extenso, en su gran mayoría evolucionan con síntomas, principalmente datos de disfunción ventricular izquierda, arritmias o isquemia residual; sin embargo, existe un grupo de pacientes que evoluciona en forma asintomática, y que debe estudiarse en forma extensa ya que la evolución puede ser muy mala, principalmente si existe isquemia residual, arritmias, disfunción ventricular, lesión arterial coronaria grave, estados comórbidos asociados o son pacientes añosos o que tienen historia de infartos previos. De acuerdo a la evolución clínica y resultados de los estudios especiales como prueba de esfuerzo, Holter, ecocardiograma con y sin fármacos, estudios de cardiología nuclear, resonancia magnética nuclear y cateterismo cardiaco con coronariografía y ventriculografía, será necesario adecuar el tratamiento farmacológico o de revascularización, ya sea con técnicas intervencionistas o quirúrgicas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. ACC/AHA Guidelines for the management of patients with myocardial infarction. J Am Coll Cardiol 1999; 34: 890-911.

  2. Fisher A, gutstein DE, Fuster V: Thrombosis and coagulation abnormalities in the acute coronary syndromes. Cardiology Clinics 1999; 17(2): 283-294.

  3. Shah PK: Plaque disruption and thrombosis. Cardiology Clinics 1999; 17(2): 271-281.

  4. Kim RJ, Wu E, Allen R, Chen EL, Parker MA, Simonetti O, et al: The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343: 1445-53.

  5. Morrow DA, Antman EM, Chalesworth A, Braunwald E: TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score, for risk assessment at presentation. Circulation 2000; 102: 2031-7.

  6. Kuri J, Martínez-Sánchez C, Moreno M, Clemente A, Virgos A, Fernández de la Vega P: Prueba de esfuerzo de bajo nivel en la fase temprana del infarto del miocardio y su correlación con la coronariografía. Arch Inst Cardiol Mex 1989; 59: 279-286.

  7. Thirmann DR, Corech J, Schulman SP: Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation 2000; 101: 2239-2246.

  8. Ross AM, Coyne KS, Moreyra E: For the GUSTO-1 angiographic investigators. Extended mortality benefit of early post-infarction reperfusion. Circulation 1998; 97: 1549-56.

  9. Gibson CM, Cannon CP, Murphy SA: For the TIMI (Thrombolysis In Myocardial Infarction ) study group: Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101: 125-30.

  10. Nunn CM, O’neill WW, Rothbaum D, Stone GW, O’keefe J, Overlie P, et al: Long-term outcome after primary angioplasty in myocardial infarction (PAMI-I) Trial. J Am Coll Cardiol 1999; 33: 640-46.

  11. Grines CL, Cox DA, Stone GW: Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 1999; 341: 489-56.

  12. Hochman JS, Sleeper LA, White hd, Dzavik V, Wong SC, Menon V, et al: One year survival following early revascularization for cardiogenic shock. JAMA 2001; 285: 190-92.

  13. Hennekens CH, Albert CM, Godfried SL: Adjunctive drug therapy of acute myocardial infarction-evidence from clinical trials. N Engl J Med 1996; 335: 1660-7.

  14. Roberts R, Roger WJ, Mueller HS, Lambrew CT, Diver DJ, Smith HC, et al: Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) II-B-Study. Circulation 1991; 83: 422-37.

  15. The norwegian multicenter study group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-7.

  16. Beta-blocker heart attack trial research group. A randomized trial of propranolol in patients with acute myocardial infarction: mortality results. JAMA 1982; 247: 1707-7.

  17. The acute infarction ramipril efficacy (AIRE) Study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-28.

  18. Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, et al: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355: 1575-81.

  19. Scandinavian simvastatin survival study group. Baseline serum cholesterol and treatment effect in the Scandinavian simvastatin survival group study (4S). Lancet 1995; 345: 1274-5.

  20. Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D: Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999; 159: 1793-1802.

  21. Jones P, Kafonek S, Laurora I, Hunninhake D: For the CURVES investigators: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-587.

  22. Fletcher GF: How to implement physical activity in primary and secondary prevention- A statement for healthcare professionals from the task force on risk reduction. Circulation 1997; 96: 355-7.




2020     |     www.medigraphic.com